Hi, I am Xinyong Liu, My LiveDNA is 86.6360
 
   
  Home
 
 
 
Dr. Xinyong Liu
 
Highest Degree: Ph.D. in Medicinal Chemistry from Shandong University, China
 
Institute: Shandong University, China
 
Area of Interest: Chemistry
  •   Rational Drug Design
  •   Synthesis
  •   HIV-1 Transactivation Inhibitors
  •   Novel Non-Nucleoside Inhibitors
 
URL: http://livedna.org/86.6360
 
My SELECTED Publications
1:   Cao, Y., X. Liu and E. De Clercq, 2009. Cessation of HIV-1 transcription by inhibiting regulatory protein rev-mediated RNA transport. Curr. HIV Res., 7: 101-108.
Direct Link  |  
2:   Chen, H., G. Li, P. Zhan, X. Guo, Q. Ding, S. Wang and X. Liu, 2013. Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. Med. Chem. Commun., 4: 827-832.
CrossRef  |  
3:   Chen, H., P. Zhan and X. Liu, 2011. Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents. Eur. J. Med. Chem., 46: 5609-5615.
CrossRef  |  PubMed  |  
4:   Chen, H., X. Liu, P. Zhan and E. De Clercq, 2010. TSG101: A novel anti-HIV-1 drug target. Curr. Med. Chem., 17: 750-758.
Direct Link  |  
5:   Chen, W., P. Zhan, D. Rai, B. Huang, J. Yang and X. Liu, 2013. Facile synthesis of derivatives of 1,1,3-Trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine: A new heterocyclic system. Heteroatoms Chem., 24: 495-501.
CrossRef  |  
6:   Chen, W., P. Zhan, E. De Clercq and X. Liu, 2012. Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors. Curr. Pharm. Des., 18: 100-112.
Direct Link  |  
7:   Chen, W., P. Zhan, E. De Clercq, C. Pannecouque, J. Balzarini, X. Jiang and X. Liu et al., 2013. Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. Bioorg. Med. Chem., 21: 7091-7100.
8:   Chen, W., P. Zhan, J. Wu, Z. Li and X. Liu, 2012. The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family. Curr. Pharm. Des., 18: 4165-4186.
Direct Link  |  
9:   Chen, X., P. Zhan, C. Pannecouque, J. Balzarini, E. De Clercq and X. Liu, 2012. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. Eur. J. Med. Chem., 51: 60-66.
CrossRef  |  
10:   Chen, X., P. Zhan, D. Li, E. De Clercq and X. Liu, 2011. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr. Med. Chem., 18: 359-376.
CrossRef  |  PubMed  |  
11:   Chen, X., P. Zhan, X. Liu, Z. Cheng and C. Meng et al., 2012. Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem., 20: 3856-3864.
CrossRef  |  
12:   Chen, X., S. Ding, P. Zhan and X. Liu, 2013. Recent advances of diaryl ether family as HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Pharm. Des., 19: 2829-2838.
Direct Link  |  
13:   Chen, X., X. Liu, Q. Meng, D. Wang and H. Liu et al., 2013. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 23: 6593-6597.
CrossRef  |  
14:   Chen, X., Y. Li, S. Ding, J. Balzarini and C. Pannecouque et al., 2013. Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. ChemMedChem, 8: 1117-1126.
CrossRef  |  
15:   Cheng, X., X. Liu and W. Xu, 2005. Recent advances in the structural modification of ligustrazine; cerebro- and cardiovascular activity of ligustrazine derivatives. D. Future, Vol. 30. 10.1358/dof.2005.030.10.927377.
CrossRef  |  Direct Link  |  
16:   Cheng, X., X. Liu and W. Xu, 2006. Synthesis of novel ligustrazine derivatives as potential platelet aggregation inhibitors. Chinese Chem. Lett., 17: 1317-1320.
17:   Cheng, X.C., X.Y. Liu, W. F. Xu, X.L. Guo and Y. Ou, 2007. Design, synthesis and biological activities of novel Ligustrazine derivatives. Bioorg. Med. Chem., 15: 3315-3320.
CrossRef  |  PubMed  |  
18:   Cheng, X.C., X.Y. Liu, W.F. Xu, X.L. Guo N. Zhang and Y. Song, 2009. Ligustrazine derivatives part 31: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents. Bioorg. Med. Chem., 17: 3018-3024.
19:   Cheng, X.C., X.Y.Liu and W.F. Xu, 2006. The preparation of novel ligustrazine derivatives as potential cerebrocardiac vascular agents. J. Chem. Res., 2006: 577-579.
Direct Link  |  
20:   Deng, L., X. Guo, L. Zhai, Y. Song and H. Chen et al., 2012. Ligustrazine derivatives. Part 4: Design, synthesis and biological evaluation of novel ligustrazine-based stilbene derivatives as potential cardiovascular agents. Chem. Biol. Drug Des., 79: 731-739.
21:   Hu, S.Q., S.Q. Mi, X.L. Jia, C.C. Fan, S.H. Chen, J. Zhang and X.Y. Liu, 2011. 3D-QSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors. Chem. J. Chinese Univ., 32: 2402-2409.
Direct Link  |  
22:   Jiang, X., P. Zhan, X. Liu and E. De Clercq, 2012. Synthesis and Anti-HIV activity evaluation of 2-(5-(naphthalen-1-yl)-1,2,3-thiadiazol-4-ylthio)-N-acetamides derivatives. Lett. Am. J. Pharm., 31: 751-755.
23:   Jiang, Y., X. Liu and E. De Clercq, 2011. New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle. Curr. Med. Chem., 18: 16-28.
CrossRef  |  PubMed  |  
24:   Kang, D., Y. Song, P. Zhan, Q. Zhang and X. Liu, 2013. Design, synthesis, and acetylcholinesterase inhibition assay of novel 9-(1-(Substituted-benzyl)piperidin-4-yl)-2-chloro-9H-purin-6-amine derivatives. J. Chem., Vol. 2013. 10.1155/2013/107302.
CrossRef  |  
25:   Li, D., P. Zhan, E. de Clercq and X. Liu, 2012. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: Lessons from the development of seven representative paradigms. J. Med. Chem., 55: 3595-3613.
CrossRef  |  
26:   Li, D., P. Zhan, H. Liu, C. Pannecouque, J. Balzarini, E. De Clercq and X. Liu, 2013. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorg. Med. Chem., 21: 2128-2134.
CrossRef  |  
27:   Li, W., J. Wu, P. Zhan, Y. Chang, C. Pannecouque, E. De Clercq and X. Liu, 2012. Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates. Int. J. Biol. Macromol., 50: 974-980.
CrossRef  |  
28:   Li, W., P. Zhan, E. De Clercq, H. Lou and X. Liu, 2013. Current drug research on PEGylation with small molecular agents. Prog. Polym. Sci., 38: 421-444.
CrossRef  |  
29:   Li, W., P. Zhan, J. Wu, Y. Chang and C. Pannecouque, E. De Clercq and X. Liu, 2011. Synthesis, influence of polymer molecular weight on drug release and anti-HIV Activity of pegylated AZT conjugates. Antiviral Res., 90: A37-A37.
Direct Link  |  
30:   Li, W., Y. Chang, P. Zhan, N. Zhang, X. Liu, C. Pannecouque and E. De Clercq, 2010. Synthesis, in vitro and in vivo release kinetics and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, zidovudine). ChemMedChem, 5: 1893-1898.
CrossRef  |  Direct Link  |  
31:   Li, X., P. Zhan, E. De Clercq and X. Liu, 2012. The HIV-1 non-nucleoside reverse transcriptase inhibitors (Part 5): Capravirine and its analogues. Curr. Med. Chem., 19: 6138-6149.
32:   Li, X., P. Zhan, H. Liu, D. Li and L. Wang et al., 2012. Arylazolyl(azinyl)thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorg. Med. Chem., 20: 5527-5536.
CrossRef  |  
33:   Li, Z., F. Yu, L. Cui, P. Zhan, S. Wang and X. Liu, 2012. Ligustrazine derivatives. Part 6: design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents. Med. Chem., 8: 928-933.
34:   Li, Z., F. Yu, L. Cui, W. Chen and S. Wang et al., 2014. Ligustrazine derivatives. Part 8: Design, synthesis and preliminary biological evaluation of novel ligustrazinyl amides as cardiovascular agents. Med. Chem., 10: 81-89.
Direct Link  |  
35:   Li, Z., P. Zhan and X. Liu, 2011. 1,3,4-Oxadiazole: A Privileged Structure in antiviral agents. Mini Rev. Med. Chem., 11: 1130-1142.
PubMed  |  
36:   Li, Z., P. Zhan, L. Naesens, E. Vanderlinden and A. Liu et al., 2012. Synthesis and preliminary biologic evaluation of 5-substituted-2-(4-substituted phenyl)-1,3-benzoxazoles as a novel class of influenza virus a inhibitors. Chem. Biol. Drug Des., 79: 1018-1024.
CrossRef  |  
37:   Li, Z., Y. Cao, P. Zhan, C. Pannecouque and J. Balzarini et al., 2013. Arylazolylthioacetanilide. Part 11: Design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Med. Chem., 9: 968-973.
Direct Link  |  
38:   Li, Z., Y. Cao, P. Zhan, C. Pannecouque, E. De Clercq and X. Liu, 2013. Synthesis and anti-HIV evaluation of novel 1,2,4-triazole derivatives as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. Lett. Drug Des. Discovery, 10: 27-34.
CrossRef  |  
39:   Lin, Y., X. Liu, R. Yan, J. Li, C. Pannecouque, M. Witvrouw and E. De Clercq, 2008. Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs). Bioorg. Med. Chem., 16: 157-163.
Direct Link  |  
40:   Liu, H., X. Wei, L. Chen, X. Liu, S. Li, X. Liu and X. Zhang, 2013. Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion injury in the rat by an antioxidant action via inhibition of NADPH oxidase and iNOS expression. Pharmacology, 92: 198-206.
CrossRef  |  
41:   Liu, X., R. Yan, N. Chen, W. Xu, M.T. Molina and S. Vega, 2006. Regioselective Synthesis of Novel N2- and N4-Substituted 7-Methylpyrazolo [4,5-e] [1,2,4]thiadiazines. Molecules, 11: 827-836.
Direct Link  |  
42:   Liu, X., N. Chen, R. Yan, W. Xu, M.T. Molina and S. Vega, 2006. Regioselective Synthesis of the Novel N4-Substituted Pyrazolo[4,5-e][1,2,4] thiadiazines as Potent HIV-1 NNRTIs. Heterocycles, 68: 1225-1232.
43:   Liu, X., P. Zhan, C. Pannecouque and E. De Clercq, 2009. Design, synthesis and anti-HIV-1 evaluation of novel arylazolylthioacetanilides as potent NNRTIS. Antiviral Res., 82: A44-A45.
44:   Liu, X., P. Zhan, R. Yan, Y. Lin, J. Li, C. Pannecouque and E. De Clercq, 2009. Design, synthesis and antiviral evaluation of novel heterocyclic compounds as HIV-1 NNRTIs. Drug Discov. Ther., 2: 25-28.
45:   Liu, X., R.Z. Yan, Y. Wang, P. Zhan and C. Pannecouque et al., 2008. Synthesis and anti-HIV activity evaluation of novel 2,4-disubstituted 7-Methyl-1,1,3-trioxo-2H,4H-Pyrazolo[4,5-e] [1,2,4]thiadiazines. Arch. Pharm. Res., 341: 216-222.
46:   Liu, X., Z. Rui and W. Xu, 2003. Synthesis of the novel liqustrazine derivatives and their protective effect on injured vascular endothelial cell damaged by hydrogen peroxide. Bioorg. Med. Chem. Lett., 13: 2123-2126.
CrossRef  |  PubMed  |  
47:   Liu, X.Y., R.Z. Yan, N.G. Chen and W.F. Xu., 2007. Regioselective Synthesis and Anti-HIV Activity of the Novel 2- and 4-Substituted Pyrazolo[4,5-e][1,2,4]thiadiazines. Chin. Chem. Lett., 18: 137-140.
48:   Liu, X.Y., W.F. Xu and J.D. Wu, 2003. Synthesis of 4-amino-5-furyl-2-yl-4h-1, 2, 4-triazole-3-thiol derivatives as a novel class of endothelin(et) receptor antagonists. Chin Chem. Lett., 14: 790-793.
49:   Mingyan, Y., Z. Li, S. Liu, C. Pannecouque, E. De Clercq and X. Liu, 2011. Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonyl -methylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Chem. Med. Chem., 6: 826-833.
50:   Ou, Y., X. Dong, X.Y. Liu, X.C. Cheng, Y.N. Cheng, L.G. Yu and X.L. Guo, 2010. Mechanism of tetramethylpyrazine analogue CXC195 inhibition of hydrogen peroxide-induced apoptosis in human endothelial cells. Biol. Pharm. Bull., 33: 432-438.
Direct Link  |  
51:   Ou, Y., X.L. Guo, L. Zhai, X.Y. Liu and Y.N. Cheng, 2010. TMPDP, a tetramethylpyrazine derivative, protects vascular endothelial cells from oxidation damage by hydrogen peroxide. Pharmazie, 65: 755-759.
Direct Link  |  
52:   Rai, D., W. Chen, Y. Tian, X. Chen and P. Zhan et al., 2013. Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs. Bioorg. Med. Chem., 21: 7398-7405.
CrossRef  |  
53:   Shan, Z.B., M.B. Chen, X.C. Dong and X.Y. Liu, 2003. q2 guided conformation selection approach of CoM FA for HIV-1 RT inhibitors. Acta Chem. Sinica, 6: 1121-1128.
54:   Song, Y., P. Zhan and X. Liu, 2013. Heterocycle-thioacetic acid motif: A privileged molecular scaffold with potent, broad-ranging pharmacological activities. Curr. Pharm. Des., 19: 7141-7154.
Direct Link  |  
55:   Song, Y., P. Zhan, D. Kang, X. Li and Y. Tian et al., 2013. Discovery of novel pyridaziylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. Med. Chem. Commun., 4: 810-816.
CrossRef  |  
56:   Song, Y., P. Zhan, E. De Clercq, X. Li, D. Rai and X. Liu, 2013. Multivalent agents: A novel concept for anti-HIV drug discovery. Curr. Med. Chem., 20: 815-832.
57:   Song, Y., P. Zhan, Q. Zhang and X. Liu, 2013. Privileged scaffolds or promiscuous binders: A glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. Curr. Pharm. Des., 19: 1528-1548.
Direct Link  |  
58:   Song, Y., Z. Fang, P. Zhan and X. Liu, 2013. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update. Curr. Med. Chem., 21: 329-355.
Direct Link  |  
59:   Song, Y.N., X.L. Guo, B.B. Zheng, X.Y. Liu, X. Dong, L.G. Yu and Y.N. Cheng, 2011. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity. Toxicol. Vitro., 25: 937-943.
CrossRef  |  PubMed  |  
60:   Sun, S.D., S.Q. Mi, J. You, J.L. Yu, S.Q. Hu and X.Y. Liu, 2013. HQSAR study and molecular design of benzimidazole derivatives as corrosion inhibitors. Acta Phys. Chim. Sin., 29: 1192-1200.
Direct Link  |  
61:   Tian, Y., D. Rai, P. Zhan, C. Pannecouque and J. Balzarini et al., 2013. Design, synthesis and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs (CBDD-RA-02-13-1571). Chem. Biol. Drug Des., 82: 384-393.
62:   Tian, Y., P. Zhan, D. Rai, J. Zhang, E. De Clercq and X. Liu, 2012. Recent advances in the research of 2,3-diaryl-1,3-thiazolidin-4-one derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Med. Chem., 19: 2026-2037.
CrossRef  |  
63:   Wang, Y., X.Y. Liu and E. De Clercq, 2009. Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof. Mini-Reviews Med. Chem., 9: 379-385.
Direct Link  |  
64:   Wu, J., X. Liu, X. Cheng, Y. Cao and D. Wang et al., 2007. Synthesis of Novel Derivatives of 4-Amino-3-(2-Furyl)-5-Mercapto-1,2,4-Triazole as Potential HIV-1 NNRTIs. Molecules, 12: 2003-2016.
65:   Yan, R.Z., X.Y. Liu, W.F. Xu, C. Pannecouque, M. Witvrouw and E. De Clercq, 2006. Synthesis and Anti-HIV Evaluation of the Novel 2-(m-Chlorobenzyl)-4- substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4,5-e][1, 2, 4]thiadiazines. Arch. Pharm. Res., 29: 957-962.
PubMed  |  
66:   Yu, F., X. Liu, P. Zhan and E. De Clercq, 2008. Recent advances in the research of HIV-1 RNase H inhibitors. Mini-Rev. Med. Chem., 8: 1243-1251.
Direct Link  |  
67:   Yu, M., E. Fan, J. Wu and X. Liu, 2011. Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Med. Chem., 18: 2376-2385.
CrossRef  |  PubMed  |  
68:   Yu, M., X. Liu and E. De Clercq, 2009. NF-κB: The inducible factors of HIV-1 transcription and their inhibitors. Mini-Reviews Med. Chem., 9: 60-69.
Direct Link  |  
69:   Yu, M., X. Liu, A. Liu, G. Du, L. Naesens, E. Vanderlinden and E. De Clercq, 2011. Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents. Chem. Biol. Drug Des., 78: 596-602.
CrossRef  |  PubMed  |  
70:   Yu, M., X. Liu, Z. Li, S. Liu, C. Pannecouque and E. De Clercq, 2009. Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonyl methylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Bioorg. Med. Chem., 17: 7749-7754.
CrossRef  |  Direct Link  |  
71:   Zhai, L., P. Zhang, R.Y. Sun, X.Y. Liu, W.G. Liu and X.L. Guo, 2012. Cytoprotective effects of CSTMP, a novel stilbene derivative, against H2O2-induced oxidative stress in human endothelial cells. Pharmacol. Rep., 63: 1469-1480.
Direct Link  |  
72:   Zhan, P. and X. Liu, 2009. Designed multiple ligands: An emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des., 36: 1893-1917.
Direct Link  |  
73:   Zhan, P. and X. Liu, 2011. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A patent review (2005 - 2010). Exp. Opin. Ther. Patents, 21: 1-80.
CrossRef  |  PubMed  |  
74:   Zhan, P. and X. Liu, 2013. Rationally designed multitarget anti-HIV agents. Curr. Med. Chem., 20: 1743-1758.
75:   Zhan, P., D. Li, J. Li, X. Chen and X. Liu, 2012. Benzimidazole heterocycle as a privileged scaffold in antiviral agents. Mini-Review Org. Chem., 9: 397-410.
CrossRef  |  
76:   Zhan, P., D. Li, X. Chen, X. Liu, E. De Clercq, 2011. Functional roles of Azoles Motif in anti-HIV agents. Curr. Med. Chem., 18:: 29-46.
CrossRef  |  PubMed  |  
77:   Zhan, P., H. Liu, X. Liu, Y. Wang, C. Pannecouque, M. Witvrouw and E. De Clercq, 2010. Synthesis and anti-HIV activity evaluation of novel N1-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. Med. Chem. Res., 19: 652-663.
78:   Zhan, P., L. Wang, H. Liu, X. Chen and X. Li et al., 2012. Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Arch. Pharmacal Res., 35: 975-986.
CrossRef  |  Direct Link  |  
79:   Zhan, P., R. Yan, X. Liu, C. Pannecouque and M. Witvrouw et al., 2011. Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl- 1,1,3-trioxo-2H,4H-pyrazolo[4,5-e] [1,2,4]thiadiazine derivatives. Drug Discov. Ther., 5: 279-285.
PubMed  |  
80:   Zhan, P., W. Chen, Z. Li, X. Li and X. Chen et al., 2012. Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. Bioorg. Med. Chem., 20: 6795-6802.
CrossRef  |  Direct Link  |  
81:   Zhan, P., W. Li, H. Chen and X. Liu, 2010. Targeting protein-protein interactions: A promising avenue of anti-HIV drug discovery. Curr. Med. Chem., 17: 3393-3409.
Direct Link  |  
82:   Zhan, P., X. Chen, D. Li, Z. Fang, E. De Clercq and X. Liu, 2013. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity and impliations for drug design. Med. Res. Rev., 33: E1-E72.
CrossRef  |  Direct Link  |  
83:   Zhan, P., X. Chen, X. Li, D. Li and Y. Tian et al., 2011. Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors. Eur. J. Med. Chem., 46: 5039-5045.
CrossRef  |  PubMed  |  Direct Link  |  
84:   Zhan, P., X. Chen, X. Liu, C. Pannecouque and L. Naesens et al., 2011. Thiazolylthioacetamides as a novel class of potential antiviral agents. Antiviral Res., 90: A67-A67.
85:   Zhan, P., X. Jiang and X. Liu, 2010. Naturally occurring and synthetic bioactive molecules as novel non-nucleoside HBV inhibitors. Mini-Rev. Med. Chem., 10: 161-171.
Direct Link  |  
86:   Zhan, P., X. Li, Z. Li, X. Chen and Y. Tian et al., 2012. Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. Bioorg. Med. Chem., 22: 7155-7162.
CrossRef  |  Direct Link  |  
87:   Zhan, P., X. Liu and E. De Clercq, 2008. Recent advances in antiviral activity of benzo/heterothiadiazine dioxide derivatives. Curr. Med. Chem., 15: 1529-1540.
Direct Link  |  
88:   Zhan, P., X. Liu and E. De Clercq, 2010. Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. Curr. Med. Chem., 17: 495-503.
Direct Link  |  
89:   Zhan, P., X. Liu and Z. Li, 2009. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. Curr. Med. Chem., 16: 2876-2889.
Direct Link  |  
90:   Zhan, P., X. Liu, J. Zhu, Z. Fang, Z. Li, C. Pannecouque and E. De Clercq, 2009. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem., 17: 5775-5781.
CrossRef  |  
91:   Zhan, P., X. Liu, Y. Cao, Y. Wang, C. Pannecouque and E. De Clercq, 2008. 1,2,3-thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 18: 5368-5371.
CrossRef  |  
92:   Zhan, P., X. Liu, Z. Fang, C. Pannecouque and E. De Clercq, 2009. 1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation. Bioorg Med Chem., 17: 6374-6379.
CrossRef  |  
93:   Zhan, P., X. Liu, Z. Fang, Z. Li, C. Pannecouque and E. De Clercq, 2009. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem., 44: 4648-4653.
CrossRef  |  Direct Link  |  
94:   Zhan, P., X. Liu, Z. Fang, Z. Li, C. Pannecouque and E. De Clercq, 2010. 1,2,3-thiadiazole thioacetanilides. Part 2. Synthesis and biological evaluation of a new series of 2-(4-(3,4-dichlorophenyl)-1,2,3-Thiadiazol-5-ylthio)acetamides as anti-HIV-1 inhibitors. Chem. Biodivers., 7: 1717-1726.
95:   Zhan, P., X. Liu, Z. Li, C. Pannecouque and E. De Clercq, 2009. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem., 16: 3903-3917.
Direct Link  |  
96:   Zhan, P., X. Liu, Z. Li, Z. Fang and Z. Li et al., 2009. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorg. Med. Chem., 17: 5920-5927.
CrossRef  |  
97:   Zhan, P., Z. Li and X. Liu, 2010. Cosalane and its analogues: A unique class of anti-HIV agents. Mini-Reviews Med. Chem., 10: 966-976.
Direct Link  |  
98:   Zhan, P., Z. Li, X. Liu and E. De Clercq, 2009. Sulfanyltriazole/tetrazoles: A promising class of HIV-1 NNRTIs. Mini-Reviews Med. Chem., 9: 1014-1023.
Direct Link  |  
99:   Zhang J., W. Ge, P. Zhan, E. De Clercq and X. Liu, 2011. Retroviral restriction factors TRIM5α: therapeutic strategy to inhibit HIV-1 replication. Curr. Med. Chem., 18: 2649-2654.
CrossRef  |  PubMed  |  
100:   Zhang, J., P. Zhan, J. Wu, Z. Li and Y. Jiang et al., 2011. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6- ((3,4-dihydroquinolin-1(2H)-yl)methyl) pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem., 19: 4366-4376.
CrossRef  |  PubMed  |  
101:   Zhang, J., X. Liu and E. De Clercq, 2009. Capsid (CA) protein as a novel drug target: Recent progress in the research of HIV-1 CA inhibitors. Mini-Reviews Med. Chem., 9: 510-518.
Direct Link  |  
102:   Zhang, L., P. Zhan, X. Chen, Z. Li and Z. Xie et al., 2014. Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Bioorg. Med. Chem., 22: 633-642.
CrossRef  |